Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01961934 : C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
PhasePhase 2/Phase 3
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

- Patients age 18-70

- Pathologically confirmed World Health Organization (WHO) grade 3 or 4 glioma

- ECOG/Zubrod 0-2

- Prior external beam radiotherapy to 59.4-60 Gray by 1.8-2 Gy fractions

- Post-radiotherapy contrast-enhanced cranial MRI obtained at least 6 weeks after the
completion of external beam radiotherapy shows enhancing anomaly
(recurrent/progressive tumor versus pseudo-progression versus radionecrosis)

- Patient completed at least a two week course of palliative steroid therapy for this
enhancing anomaly

- No prior designated therapy other than steroids for presumed radionecrosis or
recurrent tumor

- Patient with no clinical and/or radiological response to steroid therapy

- Patient eligible for stereotactic brain biopsy

- Patient eligible for focal laser therapy

Exclusion Criteria:

- Patients under the age of 18 years

- Claustrophobic patients
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01961934      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740